海创药业8000万管线喊停的背后

CPHI制药在线
Aug 18, 2025

关注并星标CPHI制药在线*展会预登记火热进行中, 扫描二维码免费领票!近日,海创药业宣布暂停投入超8000万的HP501管线研发,这并非失败者的退场,而是清醒者的战略转身。在URAT1抑制剂赛道挤满15款国产在研药物的红海里,海创选择将资源转向更前沿的HP518/537管线。这一刀切下的不仅是沉没成本,更是对“为立项而立项”行业积弊的切割。止损!8111 万投入背后的理性公式作为一款自主研发的小...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10